biostudies-literatureWeiss EEuropean Union’s Seventh Framework ProgrammeEuropean Federation of Phamaceutical Idustries and AssociationsNIAID NIH HHSNIHInnovative Medicines Initiative Joint Undertaking1912-1918https://www.ebi.ac.uk/biostudies/studies/S-EPMC9431655biostudies-literatureUnknown69(11)<h4>Background</h4>Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.<h4>Methods</h4>Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.<h4>Results</h4>The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free dayClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaElaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.PMC9431655FP7/2007–2013115523U19 AI135964Shorr AFProkocimer PThamlikitkul VRex JHPapazian LEggimann PChastre JWeiss ERello JTorres AZahar JREwig SAlder JEngelhardt MAsehnoune KLipman JPoulakou GTimsit JFWunderink RGBonten MJMKollef MTalbot GHLuna CPalmer LBDe Waele JBassetti MDimopoulos GPagani LMartin-Loeches IfalseElaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.<h4>Background</h4>Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.<h4>Methods</h4>Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.<h4>Results</h4>The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free day2019-01-01T00:00:00Z2019 Nov2025-04-19T07:29:19.381Z2025-04-19T07:29:19.381ZS-EPMC94316553072201310.1093/cid/ciz093